D

DBV Technologies SA
D

DBVT

8.55000
USD
0.41
(5.04%)
مغلق
حجم التداول
625
الربح لكل سهم
-5
العائد الربحي
-
P/E
-1
حجم السوق
233,863,961
أصول ذات صلة
ABBV
ABBV
0.160
(0.09%)
187.480 USD
A
ALK
-0.400
(-0.78%)
50.705 USD
GSK
GSK
0.355
(0.87%)
41.155 USD
NVS
NVS
0.840
(0.72%)
117.800 USD
PFE
PFE
-0.290
(-1.24%)
23.115 USD
REGN
REGN
-2.08
(-0.43%)
482.85 USD
TEVA
TEVA
-0.280
(-1.60%)
17.245 USD
المزيد
الأخبار المقالات

العنوان: DBV Technologies S.A

القطاع: Healthcare
الصناعة: Biotechnology
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.